PROFOUND MEDICAL CORP (PRN.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:PRN - CA74319B5027 - Common Stock
PRN.CA Key Statistics, Chart & Performance
The current stock price of PRN.CA is 10.25 CAD. In the past month the price increased by 13.89%. In the past year, price increased by 0.2%.
PRN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MIR.CA | MEDMIRA INC | N/A | 56.87M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 48.44M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 39.64M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 35.69M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 20.12M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 19.69M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 19.10M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 18.04M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 2.84M | ||
| VER-H.CA | VERISANTE TECHNOLOGY INC | N/A | 659.10K | ||
| VVTM.CA | VVT MED INC | N/A | 19.38M |
Related stock screener links
About PRN.CA
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Phone: 16474761350
PROFOUND MEDICAL CORP / PRN.CA FAQ
What does PROFOUND MEDICAL CORP do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
What is the current price of PRN stock?
The current stock price of PRN.CA is 10.25 CAD. The price increased by 2.09% in the last trading session.
Does PRN stock pay dividends?
PRN.CA does not pay a dividend.
What is the ChartMill rating of PROFOUND MEDICAL CORP stock?
PRN.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists PRN stock?
PRN.CA stock is listed on the Toronto Stock Exchange exchange.
What is the Price/Earnings (PE) ratio of PROFOUND MEDICAL CORP (PRN.CA)?
PROFOUND MEDICAL CORP (PRN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.83).
Can you provide the market cap for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PRN.CA) has a market capitalization of 309.45M CAD. This makes PRN.CA a Small Cap stock.
PRN.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PRN.CA. When comparing the yearly performance of all stocks, PRN.CA turns out to be only a medium performer in the overall market: it outperformed 69.7% of all stocks.
PRN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRN.CA. PRN.CA has a great financial health rating, but its profitability evaluates not so good.
PRN.CA Financial Highlights
Over the last trailing twelve months PRN.CA reported a non-GAAP Earnings per Share(EPS) of -1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93% | ||
| ROE | -122.4% | ||
| Debt/Equity | 0 |
PRN.CA Forecast & Estimates
6 analysts have analysed PRN.CA and the average price target is 15.56 CAD. This implies a price increase of 51.76% is expected in the next year compared to the current price of 10.25.
For the next year, analysts expect an EPS growth of -32.56% and a revenue growth 55.62% for PRN.CA